pain therapeutics

Showing 8 posts of 8 posts found.

Pain Therapeutics refocuses on Alzheimer’s after FDA turns down abuse-deterrent opioid painkiller

August 7, 2018
Manufacturing and Production, Research and Development, Sales and Marketing FDA, Remoxy, opioid crisis, opioids, pain therapeutics, pharma

The FDA has voted to reject Texas-based Pain Therapeutics’ abuse deterrent opioid painkiller Remoxy (oxycodone), leading the company to consider …


FDA panels vote to reject Pain Therapeutics’ abuse-deterrent opioid drug

June 27, 2018
Research and Development, Sales and Marketing Remoxy, opioid crisis, opioids, pain therapeutics, pharma

Drug development firm Pain Therapeutics has revealed that its abuse-deterrent opioid medication Remoxy has been rejected by an FDA advisory …

Blocking pain – a long-term mission for pharma research

October 5, 2011
Research and Development chronic pain, neuropathic pain, pain therapeutics

Pain is a common, yet complex, clinical problem and one which remains an area of unmet need. There are however, …

Nycomed gains new European licence for cancer pain spray

July 4, 2011
Sales and Marketing Nycomed, cancer pain, pain therapeutics

The European Commission has approved Nycomed’s Instanyl in a single-dose nasal spray for the treatment of breakthrough pain in cancer …

Grunenthal in talks to sell pain drug portfolio

May 19, 2011
Sales and Marketing Grunenthal, Stada, chronic pain, pain therapeutics

Grunenthal is negotiating a 360 million euro deal to sell Central and Eastern European rights to some of its pain …

Pfizer acquires King Pharmaceuticals for $3.6bn

October 13, 2010
Sales and Marketing King Pharmaceuticals, Pfizer, pain therapeutics

Pfizer is to purchase King Pharmaceuticals for $3.6 billion to significantly strengthen its pain portfolio and continue to diversify its …

Pfizer forced to halt pain drug trials

July 20, 2010
Research and Development Pfizer, chronic pain, pain therapeutics, tanezumab

Pfizer has been told by the FDA to suspend trials of its novel injectable biotherapeutic tanezumab for chronic low back …

Sanofi signs Indian pain drug development deal

May 5, 2010
Research and Development Glenmark, Sanofi-Aventis, chronic pain, pain therapeutics

Sanofi-Aventis has signed an agreement with Indian firm Glenmark Pharmaceuticals to develop novel agents for the treatment of chronic pain. …

Latest content